[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-339075-105":59,"doc-detail-339075-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","endosomal-recycling-inhibitors-downregulate-estrogen-receptor-alpha-and-synergise-with-endocrine-therapies","Endosomal recycling inhibitors downregulate estrogen receptor-alpha and synergise with endocrine therapies","","The study addresses treatment resistance in breast cancer and evaluates endosomal recycling inhibitors as a strategy to reduce clinically relevant cell-surface protein signaling. Using primaquine, researchers probe the molecular mechanism via reverse-phase protein array with confirmation by Western blot and RT-qPCR across HER2-positive and additional breast cancer cell lines. Functional assays test new drug combinations through MTT viability and clonogenic readouts, showing ER-α transcriptional downregulation and synergy with tamoxifen while supporting combined hormone-receptor antagonism to limit resistance.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/endosomal-recycling-inhibitors-downregulate-estrogen-receptor-alpha-and-synergise-with-endocrine-therapies/339075/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/endosomal-recycling-inhibitors-downregulate-estrogen-receptor-alpha-and-synergise-with-endocrine-therapies/339075.png","ImageObject",300,407,{"name":92,"@type":93},"Lucas Martin","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the research target in breast cancer treatment?","Question",{"text":112,"@type":113},"Drug resistance that can undermine the effectiveness of existing therapies.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is the endosomal recycling inhibitor used in the study, and how is it tested?",{"text":117,"@type":113},"Primaquine is tested using reverse-phase protein array, with confirmation by Western blot and RT-qPCR, plus drug-combination evaluation using MTT viability and clonogenic assays.",{"name":119,"@type":110,"acceptedAnswer":120},"What key biological effects and therapeutic interactions are reported?",{"text":121,"@type":113},"Endosomal recycling inhibitors downregulate estrogen receptor-alpha at the transcriptional level and synergise with tamoxifen, suggesting enhanced efficacy with hormone-receptor antagonists.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},339075,1790173400,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Breast Cancer Research and Treatment (2024) 204:631–642  \n[https://doi.org/10.1007/s10549-023-07225-2](https://doi.org/10.1007/s10549-023-07225-2)  \nEndosomal recycling inhibitors downregulate estrogen receptor‑alpha and synergise with endocrine therapies  \nKelsey A. Fletcher1 · Mai H. Alkurashi1 · Andrew J. Lindsay1  \nReceived: 25 August 2023 / Accepted: 11 December 2023 / Published online: 16 January 2024 © The Author(s) 2024  \nAbstract  \nPurpose Breast cancer (BC) accounts for roughly 30% of new cancers diagnosed in women each year; thus, this cancer type represents a substantial burden for people and health care systems. Despite the existence of effective therapies to treat BC, drug resistance remains a problem and is a major cause of treatment failure. Therefore, new drugs and treatment regimens are urgently required to overcome resistance. Recent research indicates that inhibition of the endosomal recycling pathway, an intracellular membrane trafficking pathway that returns endocytosed proteins back to the plasma membrane, may be a promising strategy to downregulate clinically relevant cell surface proteins such as HER2 and HER3, and to overcome drug resistance.  \nMethods To investigate the molecular mechanism of action of an endosomal recycling inhibitor (ERI) called primaquine, we performed a reverse-phase protein array (RPPA) assay using a HER2-positive breast cancer cell line. The RPPA findings were confirmed by Western blot and RT-qPCR in several BC cell lines. Novel drug combinations were tested by MTT cell viability and clonogenic assays.  \nResults Among the signalling molecules downregulated by ERIs were estrogen receptor-alpha (ER-α) and androgen receptor. We confirmed this finding in other breast cancer cell lines and show that downregulation occurs at the transcriptional level. We also found that ERIs synergise with tamoxifen, a standard-of-care therapy for breast cancer.  \nDiscussion Our data suggest that combining ERIs with hormone receptor antagonists may enhance their efficacy and reduce the emergence of drug resistance.  \nKeywords Estrogen receptor · Androgen receptor · Receptor recycling · Small molecules · HER3  \nIntroduction  \nBreast cancer (BC) is the most common cancer type in women, and with an ageing population, its incidence is increasing [1] . Although rare, BC also occurs in men, accounting for approximately 1% of all cancers in men [2] . BC can be categorised according to the presence or absence of several receptors, allowing it to be classified into a number of subtypes. These include the estrogen receptor (ER), human epidermal growth factor receptor 2 (HER2), and progesterone receptor (PR) . Luminal A and luminal B breast cancers both express ER. Luminal B-like breast cancer is  \n* Andrew J. Lindsay [a.lindsay@ucc.ie](a.lindsay@ucc.ie)  \n1 Membrane Trafficking and Disease Laboratory, School of Biochemistry & Cell Biology, Biosciences Institute, University College Cork, Cork T12 YT20, Ireland  \nHER2 positive and ER positive. Basal-like or triple-negative breast cancer (TNBC) does not express any of these receptors. The subtype influences diagnosis, prognosis, and treatment of the tumour [3] .  \nER is a nuclear hormone receptor that binds to estrogen in the cytoplasm and subsequently translocates into the nucleus to activate expression of estrogen responsive genes. 70–80% of BCs are ER-positive; thus, estrogen and ER are commonly targeted during treatment of this type of cancer. There are two isoforms of ER, alpha and beta, and activation of ER-α by estrogens is primarily responsible for enhanced proliferation in ER-positive BC. In contrast, ER-β has an antiproliferative effect and can counteract the tumorigenic effects of ER-α [4] . Tamoxifen is a selective estrogen receptor modulator (SERM) that binds ER and induces conformational changes in the receptor that inhibits coactivator binding, and thus, prevents its activation. While tamoxifen reduces the mortality rate in ER-positive BC, acquired","cbCaibanO4KeW0CV","https://ap.wps.com/l/cbCaibanO4KeW0CV","pdf",1313248,12,"English","# Abstract\n# Introduction\n# ER and tamoxifen in breast cancer\n# Androgen receptor in breast cancer\n# Endosomal recycling and HER2 trafficking\n# Methods\n# Results\n# Discussion","[{\"question\":\"What problem does the research target in breast cancer treatment?\",\"answer\":\"Drug resistance that can undermine the effectiveness of existing therapies.\"},{\"question\":\"What is the endosomal recycling inhibitor used in the study, and how is it tested?\",\"answer\":\"Primaquine is tested using reverse-phase protein array, with confirmation by Western blot and RT-qPCR, plus drug-combination evaluation using MTT viability and clonogenic assays.\"},{\"question\":\"What key biological effects and therapeutic interactions are reported?\",\"answer\":\"Endosomal recycling inhibitors downregulate estrogen receptor-alpha at the transcriptional level and synergise with tamoxifen, suggesting enhanced efficacy with hormone-receptor antagonists.\"}]","Endosomal recycling inhibitors downregulate estrogen receptor-alpha and synergise with endocrine therapies | PDF",1790027727,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cd46fe6642243f75b413938f23552039.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3985ed87d2c24c71b2a6fb07e8f7b939.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f996b9077c55f56ef15e25ded214b3b5.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8ebcc4d4b908447c9c5bb70173779404.webp",980,1301]